MBX Biosciences Reports Third Quarter 2025 Financial Results and Recent Corporate Highlights
Reported positive topline results from the Phase 2 Avail™ trial of once-weekly canvuparatide in hypoparathyroidism (HP) Completed upsized public offering,...